Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 and Gemcitabine in Pancreatic Cancer and Other Solid Tumors
NCT00907166Phase 2Terminated
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- May 2009
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of devimistat in pancreatic cancer (PC), bladder cancer, non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), sponsored by Cornerstone Pharmaceuticals. Started May 2009; status: terminated.
02
Drugs
devimistat
03
Conditions
pancreatic cancer (PC)bladder cancernon-small cell lung cancer (NSCLC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00907166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00907166.